195 related articles for article (PubMed ID: 31996397)
21. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
[TBL] [Abstract][Full Text] [Related]
23. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
24. [Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg AG; Gorbacheva LB; Gorbunova VA; Kozachenko VP; Lankin VZ
Biull Eksp Biol Med; 1996 Dec; 122(12):651-4. PubMed ID: 9280465
[No Abstract] [Full Text] [Related]
25. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
26. Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.
Sohn I; Jung WY; Sung CO
Gynecol Oncol; 2012 Jul; 126(1):103-8. PubMed ID: 22484402
[TBL] [Abstract][Full Text] [Related]
27. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
[TBL] [Abstract][Full Text] [Related]
30. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
Stanley B; Hollis RL; Nunes H; Towler JD; Yan X; Rye T; Dawson C; Mackean MJ; Nussey F; Churchman M; Herrington CS; Gourley C
Gynecol Oncol; 2019 Feb; 152(2):278-285. PubMed ID: 30501904
[TBL] [Abstract][Full Text] [Related]
31. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy.
Tsiatas ML; Gyftaki R; Liacos C; Politi E; Rodolakis A; Dimopoulos MA; Bamias A
Int J Gynecol Cancer; 2009 Nov; 19(8):1329-34. PubMed ID: 20009885
[TBL] [Abstract][Full Text] [Related]
32. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Duvillard P; Morice P
Int J Gynecol Cancer; 2010 Apr; 20(3):346-52. PubMed ID: 20375795
[TBL] [Abstract][Full Text] [Related]
33. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
34. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
35. The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.
Crane EK; Sun CC; Ramirez PT; Schmeler KM; Malpica A; Gershenson DM
Gynecol Oncol; 2015 Jan; 136(1):25-9. PubMed ID: 25448453
[TBL] [Abstract][Full Text] [Related]
36. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.
Tanner EJ; Black DR; Zivanovic O; Kehoe SM; Dao F; Konner JA; Barakat RR; Lichtman SM; Levine DA
Gynecol Oncol; 2012 Jan; 124(1):59-62. PubMed ID: 21982046
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of the time interval from primary surgery to intravenous chemotherapy in high grade serous ovarian cancer.
Feng Z; Wen H; Bi R; Yang W; Wu X
Gynecol Oncol; 2016 Jun; 141(3):466-470. PubMed ID: 27098361
[TBL] [Abstract][Full Text] [Related]
38. Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?
Himoto Y; Cybulska P; Shitano F; Sala E; Zheng J; Capanu M; Nougaret S; Nikolovski I; Vargas HA; Wang W; Mueller JJ; Chi DS; Lakhman Y
Gynecol Oncol; 2019 Nov; 155(2):192-200. PubMed ID: 31521322
[TBL] [Abstract][Full Text] [Related]
39. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
40. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
